Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 10, 2015, Pages 605-613

  Gaohua, L ^a   Wedagedera, J ^a   Small, B G ^a   Almond, L ^a   Romero, K ^b   Hermann, D ^c   Hanna, D ^b   Jamei, M ^a   Gardner, I ^a  

^a CERTARA UK LIMITED   (United Kingdom)

^b C Path Institute   (United States)

^c CERTARA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; ITRACONAZOLE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; EPITHELIAL LINING FLUID; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG CIRCULATION; LUNG MODEL; LUNG PARENCHYMA; LUNG VENTILATION; MONTE CARLO METHOD; MUCOCILIARY CLEARANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SURFACE AREA;

EID: 84945443982     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12034     Document Type: Article

References (50)

1. World Health Organization. Global Tuberculosis Report 2013 (World Health Organisation, Geneva, 2013).
2. Centers for Disease Control and Prevention. Treatment of Tuberculosis (American Thoracic Society, CDC, and Infectious Diseases Society of America, Atlanta, 2003).
3. Dartois, V., The path of antituberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159-167 (2014).
4. Gillespie, S.H., et al,. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587 (2014).
5. Goutelle, S., Bourguignon, L., Maire, P.H., Van Guilder, M., Conte, J.E. Jr,. &, Jelliffe, R.W., Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53, 2974-2981 (2009).
6. Shardlow, C.E., Generaux, G.T., Patel, A.H., Tai, G., Tran, T., &, Bloomer, J.C., Impact of physiologically based pharmacokinetic modeling and simulation in drug development. Drug Metab. Dispos. 41, 1994-2003 (2013).
7. Sinha, V.K., Snoeys, J., Osselaer, N.V., Peer, A.V., Mackie, C., &, Heald, D., From preclinical to human-prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm. Drug Dispos. 33, 111-121 (2012).
8. Poulin, P., &, Theil, F.P., Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
9. Rodgers, T., Leahy, D., &, Rowland, M., Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94, 1259-1276 (2005).
10. Rostami-Hodjegan, A., Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 92, 50-61 (2012).
11. Edginton, A.N., Ahr, G., Willmann, S., &, Stass, H., Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 48, 181-187 (2009).
12. Reisfeld, B., Metzler, C.P., Lyons, M.A., Mayeno, A.N., Brooks, E.J., &, Degroote, M.A., A physiologically based pharmacokinetic model for capreomycin. Antimicrob. Agents Chemother. 56, 926-934 (2012).
13. Lyons, M.A., Reisfeld, B., Yang, R.S., &, Lenaerts, A.J., A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob. Agents Chemother. 57, 1763-1771 (2013).
14. Kobashi, S., Kuramoto, K., &, Hata, Y., Functional assessment of individual lung lobes with MDCT images. In Theory and Applications of CT Imaging and Analysis (ed. Homma, N.) 95-104 (InTech, Shanghai, 2011).
15. West, J.B., Regional differences in gas exchange in the lung of erect man. J. Appl. Physiol. 17, 893-898 (1962).
16. Sakamoto, A., et al,. Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J. Pharm. Sci. 102, 3395-3406 (2013).
17. Jamei, M., Dickinson, G.L., &, Rostami-Hodjegan, A., A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009).
18. Guyton, A.C., &, Hall, J.E., Textbook of Medical Physiology 11th edn (W.B. Saunders Company, Pennsylvania, 2000).
19. Zanen, P., van der Lee, L., van der Mark, T., &, van den Bosch, J.M., Reference values for alveolar membrane diffusion capacity and pulmonary capillary blood volume. Eur. Respir. J. 18, 764-769 (2001).
20. Valentin, J., Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann. ICRP 32, 5-265 (2002).
21. Olsson, B., et al,. Pulmonary drug metabolism, clearance, and absorption. (eds. Smyth, H. & Hickey, A.) Controlled Pulmonary Drug Delivery. pp 21-50. (Springer, New York, 2011).
22. Fernandes, C.A., &, Vanbever, R., Preclinical models for pulmonary drug delivery. Expert Opin. Drug Deliv. 6, 1231-1245 (2009).
23. Chinn, D.J., Cotes, J.E., Flowers, R., Marks, A.M., &, Reed, J.W., Transfer factor (diffusing capacity) standardized for alveolar volume: validation, reference values and applications of a new linear model to replace KCO (TL/VA). Eur. Respir. J. 9, 1269-1277 (1996).
24. Wagner, P.D., Laravuso, R.B., Uhl, R.R., &, West, J.B., Continuous distributions of ventilation-perfusion ratios in normal subjects breathing air and 100 per cent O2. J. Clin. Invest. 54, 54-68 (1974).
25. Eixarch, H., Haltner-Ukomadu, E., Beisswenger, C., &, Bock, U., Drug delivery to the lung: permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS). J. Epithel. Biol. 3, 1-14 (2010).
26. Effros, R.M., &, Chinard, F.P., The in vivo pH of the extravascular space of the lung. J. Clin. Invest. 48, 1983-1996 (1969).
27. Dearden, J., &, Worth, A., In silico prediction of physicochemical properties. (Luxembourg, Institute for Health & Consumer Protection, 2007). Report no. EUR 23051 EN.
28. Jamei, M., et al,. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin. Pharmacokinet. 53, 73-87 (2014).
29. Brillault, J., De Castro, W.V., &, Couet, W., Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 54, 543-545 (2010).
30. Foster, K.A., Avery, M.L., Yazdanian, M., &, Audus, K.L., Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208, 1-11 (2000).
31. Mathia, N.R., Timoszyk, J., Stetsko, P.I., Megill, J.R., Smith, R.L., &, Wall, D.A., Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J. Drug Target. 10, 31-40 (2002).
32. Tewes, F., Brillault, J., Couet, W., &, Olivier, J.C., Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control Release 129, 93-99 (2008).
33. Togami, K., Chono, S., &, Morimoto, K., Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie 67, 389-393 (2012).
34. Castillo-Garit, J.A., Marrero-Ponce, Y., Torrens, F., &, Rotondo, R., Atom-based stochastic and non-stochastic 3D-chiral bilinear indices and their applications to central chirality codification. J. Mol. Graph. Model. 26, 32-47 (2007).
35. Goncalves, J.E., Ballerini Fernandes, M., Chiann, C., Gai, M.N., De Souza, J., &, Storpirtis, S., Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells. Biopharm. Drug Dispos. 33, 316-323 (2012).
36. Ranaldi, G., Islam, K., &, Sambuy, Y., Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 36, 1374-1381 (1992).
37. Zhang, Y., &, Yew, W.W., Mechanisms of drug resistance in mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13, 1320-1330 (2009).
38. Morris, J.B., Biologically-based modeling insights in inhaled vapor absorption and dosimetry. Pharmacol. Ther. 136, 401-413 (2012).
39. Longest, P.W., &, Holbrook, L.T., In silico models of aerosol delivery to the respiratory tract-development and applications. Adv. Drug Del. Rev. 64, 296-311 (2012).
40. Conte, J.E. Jr,., Golden, J.A., Kipps, J., Lin, E.T. & Zurlinden, E. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob. Agents Chemother. 46, 2358-2364 (2002).
41. Conte, J.E. Jr., Golden, J.A., Kipps, J., Lin, E.T., &, Zurlinden, E., Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob. Agents Chemother. 45, 2891-2896 (2001).
42. Honeybourne, D., Kees, F., Andrews, J.M., Baldwin, D., &, Wise, R., The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur. Respir. J. 7, 1275-1280 (1994).
43. Ziglam, H.M., Baldwin, D.R., Daniels, I., Andrew, J.M., &, Finch, R.G., Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50, 1011-1015 (2002).
44. Ngamtrakulpanit, L., Yu, Y., Adjei, A., Amoah, G., Gaston, B., &, Hunt, J., Identification of intrinsic airway acidification in pulmonary tuberculosis. Glob. J. Health Sci. 2, 106-110 (2010).
45. Bosquillon, C., Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99, 2240-2255 (2010).
46. Neuhoff, S., et al,. Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM). (eds. Sugiyama, Y. & Steffansen, B.) Transporters in Drug Development, Vol. 7., pp 155-177 (Springer, New York, 2013).
47. Miyama, T., et al,. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob. Agents Chemother. 42, 1738-1744 (1998).
48. Togami, K., Hayashi, Y., Chono, S., &, Morimoto, K., Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. Biopharm. Drug Dispos. 35, 321-329 (2014).
49. Roch-Ramel, F., &, Guisan, B., Renal transport of urate in humans. News Physiol. Sci. 14, 80-84 (1999).
50. Kiem, S., &, Schentag, J.J., Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52, 24-36 (2008).